[1] World Health Organization.Safety monitoring of medical products: reporting system for the general public[R/OL]. [2023-04-07].https://apps.who.int/iris/bitstream/handle/10665/336225/9789241503198-eng.pdf. [2] NMPA.NMPA announcement on issuing good pharmacovigilance practices (No.65 of2021) [EB/OL].(2021-05-13)[2023-04-07]. https://www.nmpa.gov.cn/xxgk/ggtg/qtggtg/20210513151827179.html. [3] World Health Organization. International drug monitoring: the role of national centers. Geneva: World Health Organization[R/OL]. (1972-09-20) [2023-07-17]. https://apps.who.int/iris/bitstream/handle/10665/40968/WHO_TRS_498.pdf;jsessionid=E3A16FD9966B979CFCDA0464186AD7DF?sequence=1. [4] PIRMOHAMED M, JAMES S, MEAKIN S, et al.Adverse drug reactions as cause of admission to hospital: prospective analysis of 18820 patients[J]. BMJ, 2004, 329: 15-19. [5] KONGKAEW C, NOYCE PR, ASHCROFT DM.Hospital admissions associated with adverse drug reactions: a systematic review of prospective observational studies[J]. Annals of Pharmacotherapy, 2008, 42(7/8): 1017-1025. [6] BEIJER HDE, BLAEY C.Hospitalisations caused by adverse drug reactions (ADR): a meta-analysis of observational studies[J]. Pharmacy World & Science Pws, 2002, 24(2): 46-54. [7] MEHTA UC.Pharmacovigilance: the devastating consequences of not thinking about adverse drug reactions: The burden of adverse drug reactions (ADRs) on patient care has been found to be high globally and is particularly high in South Africa[J]. Continuing Medical Education, 2011, 29(6): 247-251. [8] SIENKIEWICZ K, BURZYŃSKA M, RYDLEWSKA-LISZKOWSKA I, et al. The Importance of direct patient reporting of adverse drug reactions in the safety monitoring process[J]. Int J Environ Res Public Health, 2021,413:1-16. [9] INÁCIO P, CAVACO A, AIRAKSINEN M. The value of patient reporting to the pharmacovigilance system: a systematic review[J]. Br J Clin Pharmacol, 2017, 83: 227-246. [10] PILLAY S, MULUBWA M, VILJOEN M.Parental reporting of adverse drug reactions in South africa: an online survey[J]. Afr J Prim Health Care Fam Med, 2021, 13(1): 1-8. [11] SABBLAH GT, DARKO DM, MOGTARI H, et al.Patients' perspectives on adverse drug reaction reporting in a developing country: a case study from ghana[J]. Drug Saf, 2017, 40: 911-921. [12] JARERNSIRIPORNKUL N, PATSUREE A, KRSKA J.Public confidence in ADR identification and their views on ADR reporting: mixed methods study[J]. Eur J Clin Pharmacol, 2017, 73(2): 223-231. [13] HARIRAJ V, AZIZ Z.Patient reporting of adverse drug reactions (ADRs): survey of public awareness and predictors of confidence to report[J]. Ther Innov Regul Sci, 2018, 52(6): 757-763. [14] AL DWEIK R, STACEY D, KOHEN D, et al.Factors affecting patient reporting of adverse drug reactions: a systematic review[J]. Br J Clin Pharmacol, 2017, 83: 875-883. [15] JACOBS TG, HILDA AMPADU H, HOEKMAN J, et al.The contribution of Ghanaian patients to the reporting of adverse drug reactions: a quantitative and qualitative study[J]. BMC Public Health, 2018, 18(1): 1384-1394. [16] MATOS C, VAN HUNSEL F, JOAQUIM J.Are consumers ready to take part in the pharmacovigilance system?—a portuguese preliminary study concerning ADR reporting[J]. European Journal of Clinical Pharmacology, 2015, 71(7): 883-890. [17] European Medicines Agency. Guidelines on Good Pharmacovigilance Practices[EB/OL].(2012-06-25)[2023-05-21].https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guideline-good-pharmacovigilance-practices-gvp-module-vi-collection-management-submission-reports_en.pdf. [18] Code of Federal Regulations. 21 CFR, section 314.80. Postmarketing reporting of adverse drug experiences[EB/OL]. (2014-06-10) [2023-05-21].https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-314#314.80. [19] U.S. Food & Drug Administration. Post Marketing Safety Reporting for Human Drug and Biological Products Including Vaccines (Draft Guidance for Industry) [EB/OL]. (2020-01-29)[2023-05-21]. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/postmarketing-safety-reporting-human-drug-and-biological-products-including-vaccines. [20] MOH. Regulations for the administration of adverse drug reaction reporting and monitoring (No.81, 2011) [EB/OL]. (2011-05-04)[2023-04-13].https://gkml.samr.gov.cn/nsjg/bgt/202106/t20210629_331741.html. [21] NMPA.NMPA announcement on direct reporting of adverse reactions by drug marketing authorization holders (No. 66, 2018) [EB/OL].(2018-09-30)[2023-04-13]. https://www.nmpa.gov.cn/yaopin/ypggtg/ypqtgg/20180930174301286.html. [22] Standing Committee of the National People's Congress. Drug Administration Law of the People's Republic of China[EB/OL].(2019-08-26)[2023-04-13]. https://www.gov.cn/xinwen/2019-08/26/content_5424780.htm. [23] KRSKA J, ANDERSON C, MURPHY E, et al.How patient reporters identify adverse drug reactions: a qualitative study of reporting via the UK Yellow Card Scheme[J]. Drug Saf, 2011, 34(5): 429-436. [24] BASCH E, ARTZ D, DULKO D, et al.Patient online self-reporting of toxicity symptoms during chemotherapy[J]. J Clin Oncol, 2005, 23(15): 3552-3561. [25] KINNUNEN UM, SARANTOB K.It is time for self-incident-reporting for patients and their families in every health care organization: a literature review[J]. Stud Health Technol Inform, 2013, 192: 92-96. [26] ROLFES L, WILKES S, VAN HUNSEL F, et al.Important information regarding reporting of adverse drug reactions: a qualitative study[J]. Int J Pharm Pract, 2014, 22: 231-233. [27] ROLFES L, VAN HUNSEL F, VAN DER LINDEN L, et al. The quality of clinical information in adverse drug reaction reports by patients and healthcare professionals: a retrospective comparative analysis[J]. Drug safety, 2017, 40(7): 607-614. [28] VAN GROOTHEEST A, PASSIER J, VAN PUIJENBROEK E.Direct reporting of side effects by the patient: favourable experience in the first year[J].Nederlands Tijdschrift Voor Geneeskunde, 2005, 149(10): 529-533. [29] DEFER G, FEDRIZZI S, CHEVANNE D, et al.Adverse drug reaction reporting using a mobile device application by persons with multiple sclerosis: a cluster randomized controlled trial[J]. Drug Saf, 2021, 44: 223-233. [30] ROLFES L, VAN HUNSEL F, WILKES S, et al.Adverse drug reaction reports of patients and healthcare professionals-differences in reported information[J]. Pharmacoepidemiol Drug Saf, 2015, 24(2): 152-158. [31] BANOVAC M, CANDORE G, SLATTERY J, et al.Patient reporting in the EU: analysis of eudraVigilance Data[J]. Drug Saf, 2017, 40: 629-645. [32] BLENKINSOPP A, WILKIE P, WANG M, et al.Patient reporting of suspected adverse drug reactions: a review of published literature and international experience[J]. Br J Clin Pharmacol, 2007, 63(2): 148-156. [33] AVERY AJ, ANDERSON C, BOND CM, et al.Evaluation of patient reporting of adverse drug reactions to the UK ‘Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys[J]. Health Technol Assess, 2011, 15(1): 1-8. [34] O'DONOVAN B, RODGERS RM, COX AR, et al. Identifying and managing adverse drug reactions: Qualitative analysis of patient reports to the UK yellow card scheme[J]. Br J Clin Pharmacol, 2022, 88(7): 3434-3446. [35] DE LANGEN J, VAN HUNSEL F, PASSIER A, et al.Adverse drug reaction reporting by patients in the Netherlands: three years of experience[J]. Drug Saf, 2008, 31(6): 515-524. [36] NASRALLAH-IRLES D, CASTOT A, THOMAS L, et al.Adverse drug reactions: a pilot study on patient reporting through patient associations[J]. Therapie, 2008, 63(5): 385-392. [37] FOSTER JM, VAN DER MOLEN T, JONG-VAN DEN BERG L. Patient-reporting of side effects may provide an important source of information in clinical practice[J]. Eur J Clin Pharmacol, 2007, 63(10): 979-981. [38] European Medicines Agency. Guidelines on Good Pharmacovigilance Practices[EB/OL].(2012-06-25)[2023-07-17].https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-annex-i-definitions-rev-4_en.pdf. [39] HÄRMARK L, VAN HUNSEL F, GRUNDMARK B. ADR reporting by the general public: lessons learnt from the Dutch and Swedish Systems[J]. Drug Saf, 2015, 38(4): 337-347. [40] HAZELL L, CORNELIUS V, SHAKIR S, et al.Patient reporting of ADRs in the UK: How do patient reports affect potential signals generated by healthcare professionals?[J]. Drug Safety, 2009, 1311: 971. [41] EGBERTS TC, SMULDERS M, DE KONING FH, et al.Can adverse drug reactions be detected earlier? A comparison of reports by patients and professionals[J]. BMJ, 1996, 313(7056): 530-531. [42] VAN HUNSEL F, PASSIER A, VAN GROOTHEEST K.Comparing patients' and healthcare professionals' ADR reports after media attention: the broadcast of a Dutch television programme about the benefits and risks of statins as an example[J]. Br J Clin Pharmacol, 2009, 67(5): 558-564. [43] HAMMOND IW, RICH DS, GIBBS TG.Effect of consumer reporting on signal detection: using disproportionality analysis[J]. Expert Opinion on Drug Safety, 2007, 6(6): 705-712. [44] PARRETTA E, RAFANIELLO C, MAGRO L, et al.Improvement of patient adverse drug reaction reporting through a community pharmacist-based intervention in the Campania region of Italy[J]. Expert Opin Drug Saf, 2014, 13(Supp1): 21-29. |